Scarica l'app Stockscreener
11.01
2.56%
0.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$10.73
Aprire:
$10.65
Volume 24 ore:
1.02M
Relative Volume:
0.23
Capitalizzazione di mercato:
$2.30B
Reddito:
$503.49M
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-42.35
EPS:
-0.26
Flusso di cassa netto:
$-26.89M
1 W Prestazione:
+1.99%
1M Prestazione:
+23.24%
6M Prestazione:
+53.06%
1 anno Prestazione:
+62.08%
Intervallo 1D:
$10.51
$11.03
Intervallo di 1 settimana:
$10.46
$11.15
Portata 52W:
$5.92
$11.15
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Confronta BCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
11.02 | 2.26B | 503.49M | -53.47M | -26.89M | -0.26 |
|
HLN
Haleon Plc Adr
|
11.13 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
171.53 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.86 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.31 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Iniziato | Wedbush | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Expands Team with 7 Strategic Hires, Grants 47,250 Restricted Stock Units - Stock Titan
BioCryst stock soars to 52-week high, hits $11.14 - Investing.com India
BioCryst stock soars to 52-week high, hits $11.14 By Investing.com - Investing.com UK
BioCryst to Present New Data at 2025 Meeting of the European Aca - GuruFocus
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire Inc.
BioCryst (BCRX) Highlights Positive Data on Berotralstat for HAE Treatment | BCRX Stock News - GuruFocus
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotrals - GuruFocus
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages | BCRX Stock News - GuruFocus
BioCryst reports efficacy of HAE drug across age groups - Investing.com
BioCryst Highlights Real-world Data Showing ORLADEYO® - GlobeNewswire
BCRXBiocryst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Drugmaker targets younger patients as revenue balloons - The Business Journals
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
BioCryst to Present at Upcoming Investor Conferences | BCRX Stock News - GuruFocus
BioCryst to Present at Upcoming Investor Conferences - The Manila Times
How To Trade (BCRX) - news.stocktradersdaily.com
Bank of America Corp DE Sells 261,127 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Trading 3.62% Higher on May 22 - GuruFocus
Orladeyo reduces swelling rates in severe HAE: Real-world data - Angioedema News
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded by StockNews.com to Strong-Buy Rating - Defense World
Transcript : BioCryst Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com
D. E. Shaw & Co. Inc. Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst's Orladeyo up for FDA review in pediatric HAE patients - MSN
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid Orladeyo success, pipeline progress - Investing.com Nigeria
BNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Ameriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Best Momentum Stocks to Buy for May 9th - The Globe and Mail
BioCryst reports ORLADEYO reduces severe HAE attack rates By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals (NASDAQ:BCRX) Cut to Buy at StockNews.com - Defense World
(BCRX) Long Term Investment Analysis - news.stocktradersdaily.com
BioCryst reports ORLADEYO reduces severe HAE attack rates - Investing.com Australia
BioCryst Presents New Real-world Evidence Showing Significant an - GuruFocus
BioCryst (BCRX) Highlights Significant HAE Attack Reductions with ORLADEYO | BCRX Stock News - GuruFocus
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewswire
New Clinical Evidence: ORLADEYO Dramatically Reduces HAE Attacks in Both Teens and Severe Patients - Stock Titan
FDA to review Orladeyo application for young children with HAE - Angioedema News
FDA awards BioCryst’s Orladeyo NDA for paediatric HAE - Yahoo
The Manufacturers Life Insurance Company Sells 195,621 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst (BCRX) Gains FDA Priority Review for Pediatric ORLADEYO - GuruFocus
Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan
FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years - Contemporary Pediatrics
INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients - Contemporary Pediatrics
BioCryst’s ORLADEYO Receives FDA Priority Review - TipRanks
Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years - marketscreener.com
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® - GlobeNewswire
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.28%
2.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):